<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/169EB1A7-336E-41C1-809F-565E7D0523D0"><gtr:id>169EB1A7-336E-41C1-809F-565E7D0523D0</gtr:id><gtr:name>Biomet, Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/169EB1A7-336E-41C1-809F-565E7D0523D0"><gtr:id>169EB1A7-336E-41C1-809F-565E7D0523D0</gtr:id><gtr:name>Biomet, Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9BD7D307-E32D-4790-8E26-C85C183950DA"><gtr:id>9BD7D307-E32D-4790-8E26-C85C183950DA</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Huxtable</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G0900866"><gtr:id>64F35B2A-F9FD-467B-9159-01BFC331BD47</gtr:id><gtr:title>DPFS Devolved Portfolio (Pilot)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G0900866</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1999829</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Pathology</gtr:department><gtr:description>NPI</gtr:description><gtr:id>D42DB432-9C88-4DD2-82A7-917153CD6F66</gtr:id><gtr:impact>Once the data has been validated and any IP position confirmed; the results will be published. This is not a mulit-disciplinary collaboration.</gtr:impact><gtr:outcomeId>ghVjLx3QNCt-1</gtr:outcomeId><gtr:partnerContribution>Nottingham Prognostics has performed all the histology and used its unique algorithms to assign breast cancer classes.</gtr:partnerContribution><gtr:piContribution>Breast tissue microarray samples were provided from a cohort of Edinburgh patients. These were subject to immunohistochemical staining for a panel of biomarkers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biomet, Inc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biomet UK</gtr:department><gtr:description>Bone Scaffolds</gtr:description><gtr:id>7F216DDA-946A-441F-A9A1-A6EED72B8DCA</gtr:id><gtr:impact>Anticipated licensing agreement.</gtr:impact><gtr:outcomeId>ioF9hv2M5vo-1</gtr:outcomeId><gtr:partnerContribution>Design and manufacture of unique bone scaffold polymers.</gtr:partnerContribution><gtr:piContribution>The R&amp;amp;D team have supplied formulations of bone scaffold polymer to Biomet to test in a number of orthopaedic applications.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Discovery Partnerships with Academia</gtr:department><gtr:description>Myotonic Dystrophy</gtr:description><gtr:id>1636C576-FDEF-4107-AA5A-02B20CAD4431</gtr:id><gtr:impact>Although a lead candidate was identified GSK chose not to continue with the development programme.</gtr:impact><gtr:outcomeId>TYhuVz76Xrx-1</gtr:outcomeId><gtr:partnerContribution>Assistance with assay development</gtr:partnerContribution><gtr:piContribution>The proprietorial cell based assay will be explored by GSK to screen a coumpound librsry</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU7 Platelets</gtr:description><gtr:id>147356E5-84A9-42B1-89B4-7EDA15BC9190</gtr:id><gtr:impact>Outputs expected are publications resulting from the multi-centre testing of platelet activation kits.</gtr:impact><gtr:outcomeId>LebEViu32Vu-1</gtr:outcomeId><gtr:partnerContribution>Will allow for a multi-centre trial of new platelet activation assays</gtr:partnerContribution><gtr:piContribution>Assistance in drafting the application and performance of comparative platelet activation assays.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>InnovateUK/MRC Biomedical Catalyst</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:fundingRef>HeartLight: Heart-Rate Monitoring for Neonatal Resuscitation</gtr:fundingRef><gtr:id>5D427665-5AE6-4230-8AD8-1176B480BA13</gtr:id><gtr:outcomeId>56df12a6eb82d9.52911190</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5990000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Prof Jonathan Ball: FP7</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>864F404E-B502-446A-B9C8-2ECF7EC7E1EF</gtr:id><gtr:outcomeId>58b451e2ecc5c6.87880714</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17770</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Prof Brigitte Scammell: Wellcome Trust VIP Award</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0FCD3E5C-3710-4425-AE09-819662ABCAA9</gtr:id><gtr:outcomeId>58b452a386b491.79505431</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prof David Walker: Brain Tumour UK</gtr:description><gtr:fundingOrg>The Brain Tumour Charity</gtr:fundingOrg><gtr:id>ABA50478-F311-4598-BD0E-268571F7C7F5</gtr:id><gtr:outcomeId>58b4546b8f0e51.27839128</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Prof David Brook: Wellcome Trust Seeding Drug Discovery</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B970EB91-314C-4CE7-A29A-3E7C0EF8888C</gtr:id><gtr:outcomeId>58b4511550c2c0.23027536</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prof Brigitte Scammell: Innovate UK Award with Locate Therapeutics</gtr:description><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:id>499ABA35-774D-4DF3-B7A4-8A09F44287E6</gtr:id><gtr:outcomeId>58b45387568966.51122371</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Breast Cancer Prognostic</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E9B3ADC2-ECB6-4326-B3D3-3971B2FB8D3C</gtr:id><gtr:impact>Evaluation of Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management.</gtr:impact><gtr:outcomeId>c1YHXeT1zre</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Early Stage IP</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>1AAC04B8-3FD3-485D-A2AD-F2CB76398A2C</gtr:id><gtr:impact>Meetings with UK IPO to illustrate challenges and importance of patent applications in commercialisation of early stage medical devices.</gtr:impact><gtr:outcomeId>Q4NfibMZMee</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>&amp;quot;The Greenbottle Pharmacy Project sources wound care products from an organism, the greenbottle fly (Lucilla sericata), which is already used in the management of wounds. With Wellcome Trust, DSTL, EPSRC and TSB funding, we have identified a chymotrypsin from the secretions of L.sericata which completely digests eschar from human venous leg ulcers ex vivo and promotes alterations in fibroblast behaviour conducive to healing. This makes this particular chymotrypsin a prime candidate for development as a next generation wound debridement agent. Consequently, the enzyme has been cloned and expressed at a prototype level, and shown to mimic the effects of the whole organism in ex vivo debridement assays. Furthermore, we have incorporated the recombinant enzyme in a prototype formulation which clearly outperforms the leading competitor product Santyl. Confidence is high that the enzyme can now be developed through scale-up, formulation and toxicology to be ready for clinical evaluation within 2 years. The aim of the proposed project is to develop the product to a stage suitable for application ot wounds in patients.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>62E1109D-5848-4EB5-9B36-59B938C4DF59</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>TMyE2QscRSU</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>The Greenbottle Pharmacy Project: Next Generation Wound Debridement Products</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Blood platelets contribute to thrombus formation in veins and arteries and thrombi are the main cause of clinical events such as heart attack and stroke. Drugs that reduce platelet function are used to reduce the incidence of such events; however they can also increase risk of bleeding. We have an established track record in developing and using tests of platelet function in diagnosis and for monitoring effects of drug therapy, and as new anti-platelet drugs come on the market, there is a growing demand for such tests. Current tests are timeconsuming, technically demanding or use expensive equipment that is not readily available. Recent progress in our laboratory is such that we now have a simplified test that, with further development, could be used in a wide range of settings. The aim of this application is a) to simplify the test further in collaboration with an industrial collaborator; and b) set up clinical trials to assess its value in a range of different clinical scenarios.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>78FD7EC2-0D05-4377-9A3D-84D2D5537443</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>iEd8SnG5NfH</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Platelet function test to monitor effects of drug therapy</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Approximately 70,000 newborns/yr in the UK (10% of births) require some form of resuscitation at birth. Many of these are premature or sick increasing their risk of morbidity and mortality. Newborns resuscitated but not admitted to the neonatal unit have an increased risk of poor cognitive function in later life. Heart rate (HR) is the best indicator of effective resuscitation and is currently assessed manually using a stethoscope. However, this is subject to human error, introduces delays, and may fail to detect a sudden deterioration. Hence, there is an urgent need for a HR monitor designed specifically for newborn delivery room resuscitation as current devices are unsuitable. This device aims to improve resuscitation practice, potentially improving outcomes and reducing time spent in intensive care. We have developed and patented a HR sensor specifically for this purpose. Preliminary work has demonstrated its use on babies in intensive care. DPFS funding is sought to further develop the technology for resuscitation in the delivery room and measure key performance parameters: namely accuracy, reliability and acquisition time. By placing this device in the hands of midwives and clinicians we aim to improve resuscitation in those infants at greatest risk of short and long term sequelae.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>8E18442B-6C03-40C0-9E41-B8A963569D23</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>rXundywHPAv</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Heart rate monitor specifically designed for newborn babies requiring resuscitation at birth.</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>the group has established a series of cell lines from more than 20 DM patients. Four of these have been stably transfected with a telomerase-expressing plasmid to allow continued growth in culture. Two of the lines have also been infected with an inducible plasmid to express MyoD, which promotes differentiation into myoblasts and myotubes.</gtr:description><gtr:id>A1B8D8C7-A185-41E8-AA70-757B5D033D56</gtr:id><gtr:impact>Identification of hit compounds for treatment of myotonic dystrophy</gtr:impact><gtr:outcomeId>EZBS9nHfEQr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DM Cell Lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Use of fuzzy logic to define new patient classifications for breast cancer</gtr:description><gtr:id>6AEBA636-CF8D-4413-8E65-0E90E1C5FCB5</gtr:id><gtr:impact>Greater clarification of breast cancer classes allowing for clearer diagnosis, treatment and prognosis.</gtr:impact><gtr:outcomeId>BKBibCa2Kzq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NPI</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Nottingham Prognostics Limited</gtr:companyName><gtr:description>The business concerns the development and launch of a second-opinion website for breast cancer patients and their clinicians. The need for second opinions is increasing as treatment options multiply and patient awareness increases. The site will offer paid-for consultations which will include a personalised prognosis (initially) relating to survival.</gtr:description><gtr:id>8DBA6F6F-8644-4311-89BD-5F28AAA62351</gtr:id><gtr:impact>No Scientific staff currently employed.</gtr:impact><gtr:outcomeId>bS3UFrQWd2H</gtr:outcomeId><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>HeartLight Systems Limited</gtr:companyName><gtr:description>HeartLight Systems was set up as a joint venture between the University of Nottingham and Tioga Ltd to develop neonatal monitoring systems based on novel detection sensors.</gtr:description><gtr:id>4421B8DC-3512-4A3F-AD62-976773A007A0</gtr:id><gtr:impact>The company have recently received a TSB Biomedical Catalyst award to further develop the HeartLight monitors; the total project value is &amp;pound;1.74M.

The Path to Market toolkit developed with support from EP/I500588/1 was critical in making the case for the Biomedical Catalyst Funding and also in securing initial pump priming investment for Heartlight Systems Ltd.</gtr:impact><gtr:outcomeId>54579882eb8a47.66243135</gtr:outcomeId><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Platelet Solutions Limited</gtr:companyName><gtr:description>Platelet Solutions Ltd aims to use novel technology to measure platelet function simply and accurately in any clinical setting. A particular aim is to use the technology to optimize treatment of patients at-risk of heart attack or stroke with the effects of improving health care and reducing health costs. The technology will also be of diagnostic and therapeutic value in other diseases and in drug development programs.</gtr:description><gtr:id>3375707E-4A24-45C3-822C-25EB127750D5</gtr:id><gtr:impact>The company has only been trading since 2011. Since January 2013 they have added two 0.5FTE posts and 1FTE</gtr:impact><gtr:outcomeId>TRZoZJdrUqa</gtr:outcomeId><gtr:url>http://www.plateletsolutions.co.uk/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>A3B09C12-E11A-4690-AC96-230CBE85DD2D</gtr:id><gtr:title>Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9be1d9eccd1263440d996ea5f6aa4fa"><gtr:id>c9be1d9eccd1263440d996ea5f6aa4fa</gtr:id><gtr:otherNames>Rahman CV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58b455984f7a05.83954025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17F4897B-4B49-465E-84F2-743E5840D8B4</gtr:id><gtr:title>A biodegradable antibiotic-impregnated scaffold to prevent osteomyelitis in a contaminated in vivo bone defect model.</gtr:title><gtr:parentPublicationTitle>European cells &amp; materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174dbe72abe7062e51f82e6b5e0abc27"><gtr:id>174dbe72abe7062e51f82e6b5e0abc27</gtr:id><gtr:otherNames>McLaren JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-2262</gtr:issn><gtr:outcomeId>56caf7064c8e20.13967659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84F206B2-1877-4E03-97D1-020AD950DBA2</gtr:id><gtr:title>Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.</gtr:title><gtr:parentPublicationTitle>The journal of pathology. Clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d8b063eaeee70d4bfde640650408a2"><gtr:id>70d8b063eaeee70d4bfde640650408a2</gtr:id><gtr:otherNames>Green AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-4538</gtr:issn><gtr:outcomeId>56cae0ea8f6439.84145746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB1FD40B-0FC2-40E4-9C89-4AB3D5ECDA46</gtr:id><gtr:title>Anti-platelet therapy: ADP receptor antagonists.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f64ead1ac17a646429b82677e5c21fc8"><gtr:id>f64ead1ac17a646429b82677e5c21fc8</gtr:id><gtr:otherNames>Wijeyeratne YD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>CvcuANiNEVp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F86C6F17-73DA-44B4-9A29-87605252E9D3</gtr:id><gtr:title>The past, present and future of neutralizing antibodies for hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd35d1b54c6b5cb7a796ed9ffb36be05"><gtr:id>cd35d1b54c6b5cb7a796ed9ffb36be05</gtr:id><gtr:otherNames>Ball JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>5457975ac0a9d2.42965992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11030682-39C2-4FAE-B0F4-7D61477EA7BF</gtr:id><gtr:title>The prognostic significance of B lymphocytes in invasive carcinoma of the breast.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c06cc5d64b3e77d400f9059dbee898a4"><gtr:id>c06cc5d64b3e77d400f9059dbee898a4</gtr:id><gtr:otherNames>Mahmoud SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>EuWogm38zgF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2410D5EC-B4F6-41D0-B917-DAA8D27B9FFE</gtr:id><gtr:title>'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4c136456c433f5223b086e9308b5cb"><gtr:id>cb4c136456c433f5223b086e9308b5cb</gtr:id><gtr:otherNames>Glenn JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>54579530330e97.35982885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D273D140-3F54-4BA1-B530-C39449E03EB3</gtr:id><gtr:title>Degradation of MSCRAMM target macromolecules in VLU slough by Lucilia sericata chymotrypsin 1 (ISP) persists in the presence of tissue gelatinase activity.</gtr:title><gtr:parentPublicationTitle>International wound journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624cf84d2a309be9dfde54f7d6967493"><gtr:id>624cf84d2a309be9dfde54f7d6967493</gtr:id><gtr:otherNames>Pritchard DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-4801</gtr:issn><gtr:outcomeId>58b456c8698349.93084541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2294BA85-4BBB-4FA7-B01E-66761444E9B7</gtr:id><gtr:title>Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23ee94703873c738ed5f9f444d12ed9b"><gtr:id>23ee94703873c738ed5f9f444d12ed9b</gtr:id><gtr:otherNames>Fox SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>pm_13885_25_22866894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>103549D6-7548-4FF6-AB66-EDCC594FCA35</gtr:id><gtr:title>Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b44392fce7894332cc4a7efbd41414"><gtr:id>e1b44392fce7894332cc4a7efbd41414</gtr:id><gtr:otherNames>Conroy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>58b4553bcfc7f6.37654380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827D499D-A68E-4B90-A07C-E2E32AF86CE9</gtr:id><gtr:title>A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients.</gtr:title><gtr:parentPublicationTitle>Computers in biology and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53c830b61709c3017987efbe8b188cc4"><gtr:id>53c830b61709c3017987efbe8b188cc4</gtr:id><gtr:otherNames>Soria D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0010-4825</gtr:issn><gtr:outcomeId>pm_13885_25_20106472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48A8C3FF-C828-4EFB-B1BD-C9CADE962954</gtr:id><gtr:title>The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8cdf6a8f2da2ef2c4effb7c65e89f"><gtr:id>38a8cdf6a8f2da2ef2c4effb7c65e89f</gtr:id><gtr:otherNames>Iy? D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>pm_13885_25_22318645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CBAFA49-20D0-4772-8FDE-2D47D6407985</gtr:id><gtr:title>Degradation of eschar from venous leg ulcers using a recombinant chymotrypsin from Lucilia sericata.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bf7061fa45696c3d19d367465a8ecc1"><gtr:id>2bf7061fa45696c3d19d367465a8ecc1</gtr:id><gtr:otherNames>Telford G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>sQzhufFuauN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39364BCC-58E9-4BBB-B67A-DDCFD03CE271</gtr:id><gtr:title>The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8cdf6a8f2da2ef2c4effb7c65e89f"><gtr:id>38a8cdf6a8f2da2ef2c4effb7c65e89f</gtr:id><gtr:otherNames>Iy? D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>KRChzCcfFVk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB126E45-4AA2-400C-8E94-4097D865D67E</gtr:id><gtr:title>Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8cdf6a8f2da2ef2c4effb7c65e89f"><gtr:id>38a8cdf6a8f2da2ef2c4effb7c65e89f</gtr:id><gtr:otherNames>Iy? D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>jSKGZ3tkT4e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BED09A19-6FF1-4C72-90F3-02B1A7C68F91</gtr:id><gtr:title>High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07a12283f0dab3df9ebfe8dbc12c7130"><gtr:id>07a12283f0dab3df9ebfe8dbc12c7130</gtr:id><gtr:otherNames>Ketley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a7841578d9c97.70732148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCFA81FF-EA17-4807-B2BD-2FF58736224B</gtr:id><gtr:title>A CD44?/CD24? phenotype is a poor prognostic marker in early invasive breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fb517f8316e399752992a22a6d66400"><gtr:id>6fb517f8316e399752992a22a6d66400</gtr:id><gtr:otherNames>Ahmed MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>gJXSoctGAF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F485522-AF50-45D9-8D95-92152324D22D</gtr:id><gtr:title>Expression of a cGMP compatible Lucilia sericata insect serine proteinase debridement enzyme.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624cf84d2a309be9dfde54f7d6967493"><gtr:id>624cf84d2a309be9dfde54f7d6967493</gtr:id><gtr:otherNames>Pritchard DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>58b45628781142.97458898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DDC9B0C-707A-4EBF-9E84-906ABDDB4121</gtr:id><gtr:title>A quantifier-based fuzzy classification system for breast cancer patients.</gtr:title><gtr:parentPublicationTitle>Artificial intelligence in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53c830b61709c3017987efbe8b188cc4"><gtr:id>53c830b61709c3017987efbe8b188cc4</gtr:id><gtr:otherNames>Soria D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0933-3657</gtr:issn><gtr:outcomeId>pm_13885_25_23791088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>108C5EB8-F9CC-4193-B9D6-E958E6ECBCCC</gtr:id><gtr:title>Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5efcedeca34c9a28d82104f7306425c"><gtr:id>f5efcedeca34c9a28d82104f7306425c</gtr:id><gtr:otherNames>Rakha EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>545796253f17f7.20891331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D9B9C01-9B73-4CCA-9E16-97DE96A73B59</gtr:id><gtr:title>Incorporation of expert variability into breast cancer treatment recommendation in designing clinical protocol guided fuzzy rule system models.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e95d9181f7a17c1973269cfe560c02"><gtr:id>03e95d9181f7a17c1973269cfe560c02</gtr:id><gtr:otherNames>Garibaldi JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1532-0464</gtr:issn><gtr:outcomeId>pm_13885_25_22265814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C963CAB0-4511-40C3-BE8D-CC2FEC8722CD</gtr:id><gtr:title>Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f64ead1ac17a646429b82677e5c21fc8"><gtr:id>f64ead1ac17a646429b82677e5c21fc8</gtr:id><gtr:otherNames>Wijeyeratne YD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1751-2433</gtr:issn><gtr:outcomeId>pm_13885_25_22697589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F809BCA3-D0A3-4177-BC47-EDC3F382CAD0</gtr:id><gtr:title>A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/074173c0a663433a9cee5753743a937d"><gtr:id>074173c0a663433a9cee5753743a937d</gtr:id><gtr:otherNames>Urbanowicz RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58b458c2ba80e6.58067310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A53D8018-443D-4812-90E5-623E3B6AA25A</gtr:id><gtr:title>Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d187bf2ece3cd9969ab07154132ad50c"><gtr:id>d187bf2ece3cd9969ab07154132ad50c</gtr:id><gtr:otherNames>Britland S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>i4sDoymBHrh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E76B2DA6-7EEF-46A0-B8D5-BBA9871AEB79</gtr:id><gtr:title>Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d8b063eaeee70d4bfde640650408a2"><gtr:id>70d8b063eaeee70d4bfde640650408a2</gtr:id><gtr:otherNames>Green AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_13885_25_24008658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB91353D-6D6F-488E-A882-8A3EBA656C6D</gtr:id><gtr:title>Forehead reflectance photoplethysmography to monitor heart rate: preliminary results from neonatal patients.</gtr:title><gtr:parentPublicationTitle>Physiological measurement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34d12c1acad9c0a43d790b35349b4dbc"><gtr:id>34d12c1acad9c0a43d790b35349b4dbc</gtr:id><gtr:otherNames>Grubb MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0967-3334</gtr:issn><gtr:outcomeId>545796be0be641.19793022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFEC1F41-C519-498E-AF0B-C95679559A6F</gtr:id><gtr:title>Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>kE24GgW9dyu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1AEBF85-2754-4807-966C-0F3B2A09158B</gtr:id><gtr:title>A green light for improved resuscitation.</gtr:title><gtr:parentPublicationTitle>Midwives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f6b47377a301329abec4c2244578aa"><gtr:id>a9f6b47377a301329abec4c2244578aa</gtr:id><gtr:otherNames>Ward C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1479-2915</gtr:issn><gtr:outcomeId>56cae321418bb1.96419394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>458E5FB6-68D6-4B67-80A0-5086D27A9AA2</gtr:id><gtr:title>Maggot chymotrypsin I from Lucilia sericata is resistant to endogenous wound protease inhibitors.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bf7061fa45696c3d19d367465a8ecc1"><gtr:id>2bf7061fa45696c3d19d367465a8ecc1</gtr:id><gtr:otherNames>Telford G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>DXzCJG1Y5xD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>509FEAB9-BE44-4B89-8B83-6EB05F807F9F</gtr:id><gtr:title>A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18da1b10d29adfd82fc07718b0dc32b"><gtr:id>f18da1b10d29adfd82fc07718b0dc32b</gtr:id><gtr:otherNames>Thomas MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>545795300fa9a0.45054843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>221ECEB8-D6A3-45F1-BB04-63A090EA78DD</gtr:id><gtr:title>Marked variation in newborn resuscitation practice: a national survey in the UK.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c85c31723d207a562fa4617501370d8"><gtr:id>9c85c31723d207a562fa4617501370d8</gtr:id><gtr:otherNames>Mann C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>pm_13885_25_22245743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FDF95B9-34FE-40F6-84AC-443AB70BD2EE</gtr:id><gtr:title>Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5efcedeca34c9a28d82104f7306425c"><gtr:id>f5efcedeca34c9a28d82104f7306425c</gtr:id><gtr:otherNames>Rakha EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>5a7840d9ac03e3.82845161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFED7F3A-6CAD-4442-AFC4-D8A55B909143</gtr:id><gtr:title>An observational study investigating the effect of platelet function on outcome after colorectal surgery.</gtr:title><gtr:parentPublicationTitle>International journal of surgery (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7315973db800823f89087db9f0ad962"><gtr:id>a7315973db800823f89087db9f0ad962</gtr:id><gtr:otherNames>Keeler BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-9159</gtr:issn><gtr:outcomeId>58b4577e455505.04885149</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7B7875-571A-4ADA-AAB1-8C38DD71AEE0</gtr:id><gtr:title>Lucilia sericata chymotrypsin disrupts protein adhesin-mediated staphylococcal biofilm formation.</gtr:title><gtr:parentPublicationTitle>Applied and environmental microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/381822f6ad90a8d10bfc1e358b1525dc"><gtr:id>381822f6ad90a8d10bfc1e358b1525dc</gtr:id><gtr:otherNames>Harris LG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0099-2240</gtr:issn><gtr:outcomeId>pm_13885_25_23220967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E15BC4B-0D4E-4FE2-BB27-B3BD7807DBDA</gtr:id><gtr:title>The prognostic significance of lymphovascular invasion in invasive breast carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5efcedeca34c9a28d82104f7306425c"><gtr:id>f5efcedeca34c9a28d82104f7306425c</gtr:id><gtr:otherNames>Rakha EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>pm_13885_25_22180017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E05579F-94CA-45EE-8D30-21CBAE8132EE</gtr:id><gtr:title>Tumour-infiltrating macrophages and clinical outcome in breast cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c06cc5d64b3e77d400f9059dbee898a4"><gtr:id>c06cc5d64b3e77d400f9059dbee898a4</gtr:id><gtr:otherNames>Mahmoud SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>m2iXP1Y6CE5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F939FCB-5BD7-4E33-B414-F44A97FF0EA2</gtr:id><gtr:title>Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics.</gtr:title><gtr:parentPublicationTitle>Advances in anatomic pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5efcedeca34c9a28d82104f7306425c"><gtr:id>f5efcedeca34c9a28d82104f7306425c</gtr:id><gtr:otherNames>Rakha EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1072-4109</gtr:issn><gtr:outcomeId>i9HFWESuCY2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>180ADF34-8A97-4430-89ED-322B17EA0452</gtr:id><gtr:title>Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65568d348f54c8d9a82f22b96900a499"><gtr:id>65568d348f54c8d9a82f22b96900a499</gtr:id><gtr:otherNames>Dovlatova N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>5457952fdad323.56079972</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G0900866</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>